全球阿片黑素皮质素缺乏症治疗市场 - 行业趋势和 2029 年预测

市场分析和洞察全球阿片黑素皮质素缺乏症治疗市场

预计阿片黑素缺乏症治疗市场将在 2022-2029 年的预测期内实现市场增长。Data Bridge Market Research 分析称，在上述预测期内，市场复合年增长率将达到 5.20%。

原阿片黑素皮质素 (POMC) 缺乏症是一种单基因肥胖症，会导致严重的早发性肥胖。患有这种疾病的人除了肥胖之外，促肾上腺皮质激素 (ACTH) 的含量也很低，并且有红色的头发和苍白的皮肤。受影响的新生儿在出生时通常体重正常，但他们总是感到饥饿，这会导致过度喂养（暴食症）。到一岁时，新生儿体重增加很多并且非常肥胖。受影响的人食欲无止境，并在余生中保持肥胖。目前尚不清楚这些人是否有患上与体重相关的疾病的风险，如心脏病或 2 型糖尿病。完全性 POMC 缺乏症是由于 POMC 基因（2p23.3 染色体）功能突变的纯合或复杂杂合性缺失所致。 POMC 受瘦素调控，通过激素原转化酶裂解为黑素皮质素受体 (MC-R) 配体促肾上腺皮质激素 (ACTH) 和促黑素细胞激素 (MSH) α、β 和 γ。配体缺陷导致 MC1、MC2 和 MC4 受体缺乏活性，从而分别诱发红发、肾上腺功能不全和肥胖。

The rise in the number of patients suffering from proopiomelanocortin deficiency will act as major driver that will results in the expansion of market’s growth. Another significant factor influencing the growth rate of proopiomelanocortin deficiency treatment market is the rising healthcare expenditure. Furthermore, advancement in the medical technology, rising initiatives by public and private organisations to spread awareness about rare diseases and growing government funding are the factors that will expand the proopiomelanocortin deficiency treatment market. Other factors such as increase in the adoption of early genetic counseling and growing demand for effective therapies will positively impact the proopiomelanocortin deficiency treatment market’s growth rate.

Moreover, the rise in the research and development activities and ongoing clinical trials will provide beneficial opportunities for the proopiomelanocortin deficiency treatment market in the forecast period of 2022-2029. Also, high unmet need of current treatment and developments in healthcare technology will escalate the growth rate proopiomelanocortin deficiency treatment market in future.

However, high cost associated with the available treatment and lack of infrastructure in low-income countries will impede the growth rate of proopiomelanocortin deficiency treatment market. Additionally, the lack of specific treatment will act as major market restrain and further hinder the proopiomelanocortin deficiency treatment market growth. Less awareness will further challenge the market in the forecast period mentioned above.

This proopiomelanocortin deficiency treatment market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Proopiomelanocortin deficiency treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Proopiomelanocortin Deficiency Treatment Market Scope and Market Size

The proopiomelanocortin deficiency treatment market is segmented on the basis of treatment, diagnosis, age of onset, dosage, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

• On the basis of treatment, the proopiomelanocortin deficiency treatment market is segmented into hydrocortisone substitution therapy, setmelanotide, genetic counseling and others.
• On the basis of diagnosis, the proopiomelanocortin deficiency treatment market is segmented into blood tests, genetic tests and others.
• On the basis of age of onset, the proopiomelanocortin deficiency treatment market is segmented into infancy and neonatal.
• On the basis of dosage, the proopiomelanocortin deficiency treatment market is segmented into injection, tablets and others.
• On the basis of route of administration, the proopiomelanocortin deficiency treatment market is segmented into oral, parenteral and others.
• On the basis of end-users, the proopiomelanocortin deficiency treatment market is segmented into clinic, hospital and others.

The proopiomelanocortin deficiency treatment market is also segmented on the basis of distribution channel into hospital pharmacy, retail pharmacy and online pharmacy.

Proopiomelanocortin Deficiency Treatment Market Country Level Analysis

Proopiomelanocortin deficiency treatment market is analyzed and market size information is provided by the country, treatment, diagnosis, age of onset, dosage, route of administration, end-users and distribution channel as referenced above.

The countries covered in the proopiomelanocortin deficiency treatment market report are the U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa.

North America dominates the proopiomelanocortin deficiency treatment market due to the presence of major key players, high disposable income and well-developed healthcare infrastructure in this region. Asia-Pacific is expected to grow during the forecast period of 2022-2029 due to the increasing patient pool, rising investment in the healthcare sector, and growing government support.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

患者流行病学分析

原阿片黑素皮质素缺乏症治疗市场还为您提供详细的市场分析，用于患者分析、预后和治疗。患病率、发病率、死亡率、依从率是报告中提供的一些数据变量。分析流行病学对市场增长的直接或间接影响，以创建更稳健、更队列的多元统计模型，用于预测增长期的市场。

竞争格局和全球阿片黑素皮质素缺乏症治疗市场份额分析

原阿片黑素皮质素缺乏症治疗市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、公司优势和劣势、产品发布、临床试验渠道、产品批准、专利、产品宽度和广度、应用优势、技术生命线曲线。以上提供的数据点仅与公司对原阿片黑素皮质素缺乏症治疗市场研究的关注有关。

原阿片黑素皮质素缺乏症治疗市场的一些主要参与者包括 Rhythm Pharmaceuticals, Inc.、Sanofi、WOCKHARDT、Akorn, Incorporated Merck KGaA、Astellas Pharma Inc.、Pfizer Inc.、Teva Pharmaceutical Industries Ltd.、GlaxoSmithKline plc、Lannett、Aspen Holdings、Novartis AG、Bausch Health Companies Inc.、Bayer AG、Alcon Vision LLC、Solvay、Hikma Pharmaceuticals PLC、Dow、Salix Pharmaceuticals 和 Casper Pharma 等。

SKU-67543